Read our systematic review on patient-reported outcomes in metastatic breast cancer

January 29th, 2020

There is little consensus on how PRO and HRQoL data should be analyzed in randomized clinical trials. This systematic review evaluates the current situation in the field of metastatic breast cancer, revealing the many statistical issues that need to be addressed to improve the analysis and interpretation of PRO data.

View article

Want to know more
about SISAQOL-IMI?

CONTACT US